Skip to main content

Advertisement

Articles

Page 1 of 35

  1. Controversies exist regarding the optimal blood pressure (BP) level that is safe and provides cardiovascular protection in patients with type 2 diabetes mellitus (T2DM) and coexistent coronary artery disease. ...

    Authors: Ying Shen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Lin Lu, Feng Hua Ding and Wei Feng Shen

    Citation: Cardiovascular Diabetology 2019 18:160

    Content type: Review

    Published on:

  2. Microvascular complications (MC) have been claimed to increase the risk for cardiovascular disease in diabetic subjects. However, the effect of MC burden on the risk of major vascular outcomes and all-cause mo...

    Authors: Monia Garofolo, Elisa Gualdani, Rosa Giannarelli, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stefano Del Prato and Giuseppe Penno

    Citation: Cardiovascular Diabetology 2019 18:159

    Content type: Original investigation

    Published on:

  3. Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however re...

    Authors: Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda and Koichi Node

    Citation: Cardiovascular Diabetology 2019 18:158

    Content type: Original investigation

    Published on:

  4. Both type 1 and type 2 diabetes are well-established risk factors for cardiovascular disease and early mortality. However, few studies have directly compared the hazards of cardiovascular outcomes and prematur...

    Authors: You-Bin Lee, Kyungdo Han, Bongsung Kim, Seung-Eun Lee, Ji Eun Jun, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin and Jae Hyeon Kim

    Citation: Cardiovascular Diabetology 2019 18:157

    Content type: Original investigation

    Published on:

  5. Heart failure (HF) is a common cardiovascular complication of type 2 diabetes (T2D). This secondary analysis investigated baseline factors and treatment differences associated with risk of hospitalization for ...

    Authors: Richard E. Pratley, Mansoor Husain, Ildiko Lingvay, Thomas R. Pieber, Thomas Mark, Hans A. Saevereid, Daniel Vega Møller and Bernard Zinman

    Citation: Cardiovascular Diabetology 2019 18:156

    Content type: Original investigation

    Published on:

  6. Lower-extremity peripheral artery disease (LE-PAD) and coronary artery disease (CAD) are both pathologically rooted in atherosclerosis, and their shared clinical features regarding the exposure to cardiovascul...

    Authors: Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Masahiko Fujihara, Toshiro Shinke, Tetsuya Amano and Yuji Ikari

    Citation: Cardiovascular Diabetology 2019 18:155

    Content type: Original investigation

    Published on:

  7. Prediabetes has recently been associated with subclinical atheromatous disease in the middle-aged population. Our aim was to characterize atheromatous plaque burden by the number of affected territories and th...

    Authors: Enric Sánchez, Àngels Betriu, Carolina López-Cano, Marta Hernández, Elvira Fernández, Francisco Purroy, Marcelino Bermúdez-López, Cristina Farràs-Sallés, Silvia Barril, Reinald Pamplona, Ferran Rius, Cristina Hernández, Rafael Simó and Albert Lecube

    Citation: Cardiovascular Diabetology 2019 18:154

    Content type: Original investigation

    Published on:

  8. Diabetes has been reported to be associated with carotid artery plaque (CAP). However, it remains unclear whether hemoglobin A1c (HbA1c) level, a marker for long-term glycemic status, is associated with altere...

    Authors: Renying Xu, Ting Zhang, Yanping Wan, Zhuping Fan and Xiang Gao

    Citation: Cardiovascular Diabetology 2019 18:153

    Content type: Original investigation

    Published on:

  9. Daily glucose variability may contribute to vascular complication development irrespective of mean glucose values. The incremental glucose peak (IGP) during an oral glucose tolerance test (OGTT) can be used as...

    Authors: Yuri D. Foreman, Martijn C. G. J. Brouwers, Tos T. J. M. Berendschot, Martien C. J. M. van Dongen, Simone J. P. M. Eussen, Marleen M. J. van Greevenbroek, Ronald M. A. Henry, Alfons J. H. M. Houben, Carla J. H. van der Kallen, Abraham A. Kroon, Koen D. Reesink, Miranda T. Schram, Nicolaas C. Schaper and Coen D. A. Stehouwer

    Citation: Cardiovascular Diabetology 2019 18:152

    Content type: Original investigation

    Published on:

  10. The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special intere...

    Authors: Cristina Razquin, Miguel Ruiz-Canela, Clary B. Clish, Jun Li, Estefania Toledo, Courtney Dennis, Liming Liang, Albert Salas-Huetos, Kerry A. Pierce, Marta Guasch-Ferré, Dolores Corella, Emilio Ros, Ramon Estruch, Enrique Gómez-Gracia, Montse Fitó, Jose Lapetra…

    Citation: Cardiovascular Diabetology 2019 18:151

    Content type: Original investigation

    Published on:

  11. Insulin resistance (IR) is considered a pivotal risk factor for cardiometabolic diseases, and the triglyceride–glucose index (TyG index) has emerged as a reliable surrogate marker of IR. Although several recen...

    Authors: Erfei Luo, Dong Wang, Gaoliang Yan, Yong Qiao, Bo Liu, Jiantong Hou and Chengchun Tang

    Citation: Cardiovascular Diabetology 2019 18:150

    Content type: Original investigation

    Published on:

  12. Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL...

    Authors: Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic and Lawrence A. Leiter

    Citation: Cardiovascular Diabetology 2019 18:149

    Content type: Original investigation

    Published on:

  13. Excessive reactive oxygen species from endothelial mitochondria in type 2 diabetes individuals (T2DM) may occur through multiple related mechanisms, including production of mitochondrial reactive oxygen specie...

    Authors: Mamatha Kakarla, Venkata K. Puppala, Sudhi Tyagi, Amberly Anger, Kathryn Repp, Jingli Wang, Rong Ying and Michael E. Widlansky

    Citation: Cardiovascular Diabetology 2019 18:148

    Content type: Original investigation

    Published on:

  14. Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help ...

    Authors: Annunziata Nusca, Dario Tuccinardi, Claudio Proscia, Rosetta Melfi, Silvia Manfrini, Antonio Nicolucci, Antonio Ceriello, Paolo Pozzilli, Gian Paolo Ussia, Francesco Grigioni and Germano Di Sciascio

    Citation: Cardiovascular Diabetology 2019 18:147

    Content type: Original investigation

    Published on:

  15. Reverse cholesterol transport (RCT) is an important cardioprotective mechanism and the decrease in cholesterol efflux can result in the dyslipidemia. Although liraglutide, a glucagon like peptide-1 analogue, h...

    Authors: Ya-Ru Wu, Xiao-Yun Shi, Chun-Yan Ma, Yue Zhang, Rui-Xia Xu and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2019 18:146

    Content type: Original investigation

    Published on:

  16. Mortality attributable to heart failure remains high. The prevalence of heart failure in patients with diabetes mellitus ranges from 19 to 26%. It is estimated that up to 21.1 million adults in the United Stat...

    Authors: Marcello Ricardo Paulista Markus, Susanne Rospleszcz, Till Ittermann, Sebastian Edgar Baumeister, Sabine Schipf, Ulrike Siewert-Markus, Roberto Lorbeer, Corinna Storz, Violetta Ptushkina, Annette Peters, Christa Meisinger, Fabian Bamberg, Matthias Nauck, Martin Bahls, Henry Völzke, Stephan Burkhard Felix…

    Citation: Cardiovascular Diabetology 2019 18:145

    Content type: Original investigation

    Published on:

  17. Aim of this study was to evaluate the relationship of plasma PCSK9 with metabolic and inflammatory profile and coronary atherosclerotic burden in patients with suspected CAD enrolled in the EVINCI study.

    Authors: Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina and Danilo Neglia

    Citation: Cardiovascular Diabetology 2019 18:144

    Content type: Original investigation

    Published on:

  18. Excess fat deposition could induce phenotypic changes of perivascular adipose tissue (PVAT remodeling), which may promote the progression of atherosclerosis via modulation of adipocytokine secretion. However, ...

    Authors: Yusaku Mori, Michishige Terasaki, Munenori Hiromura, Tomomi Saito, Hideki Kushima, Masakazu Koshibu, Naoya Osaka, Makoto Ohara, Tomoyasu Fukui, Hirokazu Ohtaki, Hirano Tsutomu and Sho-ichi Yamagishi

    Citation: Cardiovascular Diabetology 2019 18:143

    Content type: Original investigation

    Published on:

  19. Hyperglycemia in the setting of an acute coronary syndrome (ACS) impacts short term outcomes, but little is known about longer term effects. We therefore designed this study to firstly determine the associatio...

    Authors: Patric Winzap, Allan Davies, Roland Klingenberg, Slayman Obeid, Marco Roffi, François Mach, Lorenz Räber, Stephan Windecker, Christian Templin, Fabian Nietlispach, David Nanchen, Baris Gencer, Olivier Muller, Christian M. Matter, Arnold von Eckardstein and Thomas F. Lüscher

    Citation: Cardiovascular Diabetology 2019 18:142

    Content type: Original investigation

    Published on:

  20. Long-term treatment with up to 1.8 mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investiga...

    Authors: Natia Peradze, Olivia M. Farr, Nikolaos Perakakis, Iolanda Lázaro, Aleix Sala-Vila and Christos S. Mantzoros

    Citation: Cardiovascular Diabetology 2019 18:141

    Content type: Original investigation

    Published on:

  21. Gestational diabetes mellitus (GDM) is defined as the presence of high blood glucose levels with the onset, or detected for the first time during pregnancy, as a result of increased insulin resistance. GDM may...

    Authors: A. Lorenzo-Almorós, T. Hang, C. Peiró, L. Soriano-Guillén, J. Egido, J. Tuñón and Ó. Lorenzo

    Citation: Cardiovascular Diabetology 2019 18:140

    Content type: Review

    Published on:

  22. The aim of the present study was to identify a threshold for the cholesterol level at which the risk of cardiovascular disease (CVD) begins to increase in people with type 2 diabetes mellitus (DM).

    Authors: Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song and Hyuk-Sang Kwon

    Citation: Cardiovascular Diabetology 2019 18:139

    Content type: Original investigation

    Published on:

  23. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanism...

    Authors: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz and Rury R. Holman

    Citation: Cardiovascular Diabetology 2019 18:138

    Content type: Original investigation

    Published on:

  24. Visceral fat area (VFA) is a good surrogate marker of obesity-related disorders, such as hypertension, dyslipidemia and glucose intolerance. Although estimating the VFA by X-ray computed tomography (CT) is the...

    Authors: Yoko Omura-Ohata, Cheol Son, Hisashi Makino, Ryo Koezuka, Mayu Tochiya, Tamiko Tamanaha, Ichiro Kishimoto and Kiminori Hosoda

    Citation: Cardiovascular Diabetology 2019 18:137

    Content type: Original investigation

    Published on:

  25. Diabetes mellitus (DM) or pre-diabetes status is closely associated with features of vulnerable coronary lesions in patients with stable coronary heart disease or acute coronary syndrome. However, the associat...

    Authors: Zhaoxue Sheng, Peng Zhou, Chen Liu, Jiannan Li, Runzhen Chen, Jinying Zhou, Li Song, Hanjun Zhao and Hongbing Yan

    Citation: Cardiovascular Diabetology 2019 18:136

    Content type: Original investigation

    Published on:

  26. Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs wi...

    Authors: Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman

    Citation: Cardiovascular Diabetology 2019 18:135

    Content type: Original investigation

    Published on:

  27. The aim of the present study is to examine the effects of free fatty acids (FFAs) on major cardiovascular events (MACEs) in patients with stable coronary artery disease (CAD) and different glucose metabolism s...

    Authors: Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Jing Sun, Qian Dong and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2019 18:134

    Content type: Original investigation

    Published on:

  28. The pathogenesis and cardiovascular impact of type 2 diabetes (T2D) may be different in South Asians compared with other ethnic groups. The phenotypic characterization of diabetic cardiomyopathy remains debate...

    Authors: Elisabeth H. M. Paiman, Huub J. van Eyk, Maurice B. Bizino, Ilona A. Dekkers, Paul de Heer, Johannes W. A. Smit, Ingrid M. Jazet and Hildo J. Lamb

    Citation: Cardiovascular Diabetology 2019 18:133

    Content type: Original investigation

    Published on:

  29. Diabetes mellitus (DM) is a major cause of morbidity and mortality following heart transplantation (HT), with 21% and 35% of survivors being affected within 1 and 5 years following HT, respectively. Magnesium ...

    Authors: Yael Peled, Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Enrique Z. Fisman, Dov Freimark, Robert Klempfner, Leonid Sternik and Michael Shechter

    Citation: Cardiovascular Diabetology 2019 18:132

    Content type: Original investigation

    Published on:

  30. Accumulating evidence has shown that type 2 diabetes (T2D) and coronary artery disease (CAD) may stem from a ‘common soil’. The aim of our study was to examine the association between genetic predisposition to...

    Authors: Qiwen Zheng, Jie Jiang, Yong Huo and Dafang Chen

    Citation: Cardiovascular Diabetology 2019 18:131

    Content type: Original investigation

    Published on:

  31. Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with d...

    Authors: Julie R. Lundgren, Kristine Færch, Daniel R. Witte, Anna E. Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Jens J. Holst, Dorte Vistisen, Marit E. Jørgensen, Signe S. Torekov and Nanna B. Johansen

    Citation: Cardiovascular Diabetology 2019 18:130

    Content type: Original investigation

    Published on:

  32. Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated...

    Authors: Milton Packer

    Citation: Cardiovascular Diabetology 2019 18:129

    Content type: Commentary

    Published on:

  33. Being obese or underweight, and having diabetes are important risk factors for new-onset atrial fibrillation (AF). However, it is unclear whether there is any interaction between body weight and diabetes in re...

    Authors: Yun Gi Kim, Kyung-Do Han, Jong-Il Choi, Ki Yung Boo, Do Young Kim, Suk-Kyu Oh, Kwang-No Lee, Jaemin Shim, Jin Seok Kim and Young-Hoon Kim

    Citation: Cardiovascular Diabetology 2019 18:128

    Content type: Original investigation

    Published on:

  34. Dyslipidaemia and low-grade inflammation are central in atherogenesis and linked to overweight and physical inactivity. Lifestyle changes are important in secondary prevention of coronary artery disease (CAD)....

    Authors: Lene Rørholm Pedersen, Rasmus Huan Olsen, Christian Anholm, Arne Astrup, Jesper Eugen-Olsen, Mogens Fenger, Lene Simonsen, Rosemary L. Walzem, Steen Bendix Haugaard and Eva Prescott

    Citation: Cardiovascular Diabetology 2019 18:127

    Content type: Original investigation

    Published on:

  35. Pericoronary adipose tissue inflammation might lead to the development and destabilization of coronary plaques in prediabetic patients. Here, we evaluated inflammation and leptin to adiponectin ratio in perico...

    Authors: Celestino Sardu, Nunzia D’Onofrio, Michele Torella, Michele Portoghese, Francesco Loreni, Simone Mureddu, Giuseppe Signoriello, Lucia Scisciola, Michelangela Barbieri, Maria Rosaria Rizzo, Marilena Galdiero, Marisa De Feo, Maria Luisa Balestrieri, Giuseppe Paolisso and Raffaele Marfella

    Citation: Cardiovascular Diabetology 2019 18:126

    Content type: Original investigation

    Published on:

  36. Insulin resistance (IR) is considered as a risk factor for atrial fibrillation (AF) even before diabetes develops. The pathophysiology and underlying mechanism are largely unclear.

    Authors: Yi-Hsin Chan, Gwo-Jyh Chang, Ying-Ju Lai, Wei-Jan Chen, Shang-Hung Chang, Li-Man Hung, Chi-Tai Kuo and Yung-Hsin Yeh

    Citation: Cardiovascular Diabetology 2019 18:125

    Content type: Original investigation

    Published on:

  37. Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing ca...

    Authors: Boris Fishman, Gadi Shlomai, Gilad Twig, Estela Derazne, Alexander Tenenbaum, Enrique Z. Fisman, Adi Leiba and Ehud Grossman

    Citation: Cardiovascular Diabetology 2019 18:124

    Content type: Original investigation

    Published on:

  38. Patients with Diabetes mellitus (DM) are susceptible to coronary artery disease (CAD). However, the impact of DM on plaque progression in the non-stented segments of stent-implanted patients has been rarely re...

    Authors: Rui Shi, Ke Shi, Zhi-gang Yang, Ying-kun Guo, Kai-yue Diao, Yue Gao, Yi Zhang and Shan Huang

    Citation: Cardiovascular Diabetology 2019 18:123

    Content type: Original investigation

    Published on:

  39. Coronary calcification is associated with high risk for cardiovascular events. However, its impact on plaque vulnerability is incompletely understood. In the present study we defined the intrinsic calcificatio...

    Authors: Sebastian Reith, Andrea Milzi, Enrico Domenico Lemma, Rosalia Dettori, Kathrin Burgmaier, Nikolaus Marx and Mathias Burgmaier

    Citation: Cardiovascular Diabetology 2019 18:122

    Content type: Original investigation

    Published on:

  40. Both obesity and type 2 diabetes are important risk factors for atrial fibrillation (AF), possibly because they both cause an expansion of epicardial adipose tissue, which is the source of proinflammatory adip...

    Authors: Milton Packer

    Citation: Cardiovascular Diabetology 2019 18:121

    Content type: Hypothesis

    Published on:

  41. To compare the cardiovascular event risk in type 2 diabetes patients newly receiving dapagliflozin vs. empagliflozin.

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang and Edward Chia-Cheng Lai

    Citation: Cardiovascular Diabetology 2019 18:120

    Content type: Original investigation

    Published on:

  42. Recently, several randomized trials have noted improved outcomes with staged percutaneous coronary intervention (PCI) of nonculprit vessels in patients with ST-segment elevation myocardial infarction (STEMI) a...

    Authors: Kongyong Cui, Shuzheng Lyu, Hong Liu, Xiantao Song, Fei Yuan, Feng Xu, Min Zhang, Wei Wang, Mingduo Zhang, Dongfeng Zhang and Jinfan Tian

    Citation: Cardiovascular Diabetology 2019 18:119

    Content type: Original investigation

    Published on:

  43. Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Reduced cardiovascular mortality and morbidity have been reported in non-HT patients treat...

    Authors: Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Robert Klempfner, Enrique Z. Fisman, Elad Maor, Tal Ovdat, Sergei Amunts, Leonid Sternik and Yael Peled

    Citation: Cardiovascular Diabetology 2019 18:118

    Content type: Original investigation

    Published on:

  44. Complication screening is recommended for patients with type 2 diabetes (T2D), but the optimal screening intensity and schedules are unknown. In this study, we evaluated whether intensive versus standard compl...

    Authors: Mario Luca Morieri, Enrico Longato, Marta Mazzucato, Barbara Di Camillo, Arianna Cocchiglia, Lorenzo Gubian, Giovanni Sparacino, Angelo Avogaro, Gian Paolo Fadini and Saula Vigili de Kreutzenberg

    Citation: Cardiovascular Diabetology 2019 18:117

    Content type: Original investigation

    Published on:

  45. To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

    Authors: Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott and Rury R. Holman

    Citation: Cardiovascular Diabetology 2019 18:116

    Content type: Original investigation

    Published on:

  46. EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular di...

    Authors: Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč…

    Citation: Cardiovascular Diabetology 2019 18:115

    Content type: Commentary

    Published on:

  47. Cardiac fat is a cardiovascular biomarker but its importance in patients with type 2 diabetes is not clear. The aim was to evaluate the predictive potential of epicardial (EAT), pericardial (PAT) and total car...

    Authors: Regitse H. Christensen, Bernt Johan von Scholten, Christian S. Hansen, Magnus T. Jensen, Tina Vilsbøll, Peter Rossing and Peter G. Jørgensen

    Citation: Cardiovascular Diabetology 2019 18:114

    Content type: Original investigation

    Published on:

  48. In the light of growing global epidemic of type 2 diabetes mellitus (T2DM), significant efforts are made to discover next-generation biomarkers for early detection of the disease. Multiple mechanisms including...

    Authors: Justyna Pordzik, Daniel Jakubik, Joanna Jarosz-Popek, Zofia Wicik, Ceren Eyileten, Salvatore De Rosa, Ciro Indolfi, Jolanta M. Siller-Matula, Pamela Czajka and Marek Postula

    Citation: Cardiovascular Diabetology 2019 18:113

    Content type: Review

    Published on:

  49. Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new ...

    Authors: Yue Fei, Man-Fung Tsoi and Bernard Man Yung Cheung

    Citation: Cardiovascular Diabetology 2019 18:112

    Content type: Original investigation

    Published on:

  50. There is no clearly defined temporal relationship between arterial stiffness and diabetes. We aimed to investigate the prospective association between baseline brachial–ankle pulse wave velocity (baPWV) and th...

    Authors: Yuanyuan Zhang, Panpan He, Youbao Li, Yan Zhang, Jianping Li, Min Liang, Guobao Wang, Genfu Tang, Yun Song, Binyan Wang, Chengzhang Liu, Lishun Liu, Yimin Cui, Xiaobin Wang, Yong Huo, Xiping Xu…

    Citation: Cardiovascular Diabetology 2019 18:111

    Content type: Original investigation

    Published on:

journal logo
Submit manuscript

Annual Journal Metrics

Advertisement

Cardiovascular Diabetology

ISSN: 1475-2840

Contact us